 |
인쇄하기
취소
|
New dosage technology clears sibutramine patent huddles.
A new dosage technology for sibutramine, the main active substance of a top anti-obesity drug, Reductil, has been developed, attracting keen interests to the pharmaceutical industry.
The technology developer, CTC Bio, was a successful bio venture company in Korea, who already filed the PTC for an international patent for the sibutramine new dosage technology.
The new technology may elimin...
The technology developer, CTC Bio, was a successful bio venture company in Korea, who already filed the PTC for an international patent for the sibutramine new dosage technology.
The new technology may elimin...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.